Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,901–2,000 of 2,656
Megiani, I. N., Peruche, P. R. C. M., Freitas, R. C. D. O., Moura, M. D. P., Pereira, J. V. G., Vidal, V. M. D. S., Serrano, L. C., & da Silva, A. P. (2024) · doi:10.22533/at.ed.4682412048 · Cited by 1
USO DE PLATAFORMAS DIGITAIS PARA FACILITAR RELACIONAMENTOS AFETIVO-SEXUAIS NA PANDEMIA DA COVID-19
Oliveira, E. M., Faustino, D. C. F., de Souza, G. L. B., Suto, C. S. S., Bampi, L. N. D. S., Pegoraro, V. A., Coelho, H. T., Fontana, T. B., & de Almeida, S. R. (2024) · doi:10.22533/at.ed.46824120417
Krüger, T. (2024) · Nephrologie aktuell · doi:10.1055/a-2214-3093
Hypertonietherapie bei Nierenerkrankungen: Wie den Blutdruck optimal in den CKD-Stadien senken?
Boger, L., & Saritas, T. (2024) · Nephrologie aktuell · doi:10.1055/a-2215-3675
Sodium glucose transporters inhibitors in the management of heart failure
Singh, R. B., Chakravorty, S., Elmaraghi, O., Nabavizadeh, F., Elkilany, G. N., Jain, M., Shukla, A. K., Agarwal, A., Yaduvanshi, A., Mahajan, S., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822972-9.00036-5
Immunglobulin-A-Vaskulitis (IgAV)
Rose, K., Turner, J., & Iking‐Konert, C. (2024) · Rheuma Plus / Schweiz · doi:10.1007/s44332-024-00015-y
Inhibidores del cotransportador sodio-glucosa 2, nueva droga para el arsenal reumatológico?
Jurado, M. C. (2024) · Revista Reumatología al Día. · doi:10.62484/rad.v18i1.7913
(Focused on heart failure treatment according to the updated 2023 guidelines)
Brotánek, J. (2024) · Cor et Vasa · doi:10.33678/cor.2024.025
Cai, Y., Zou, H., Hu, R., Chen, H., Yang, G., & Gong, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1376446
I. Sglt2 Inhibitors as Chronic Kidney Disease Therapeutics and Future Prospects
Fukami, K. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.761
IV. Current Treatment of IgA Nephropathy
Nihei, Y., & Suzuki, Y. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.784
de Salles, M. L. F., Recla, B. B., da Cruz, M. A., & de Souza, S. F. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408940
de Almeida, M. D. N. C. S., Barros, A. C. L., Dias, L. G. D. F., & Gandra, S. A. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408949
Marcondes, L. C. R., Cardoso, A. L. M. H., Costa, L. M., & Martins, L. E. S. J. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408955
de Almeida, M. D. N. C. S., Siqueira, D. F., Alves, O. A. L., & Andrade, W. M. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408953
Corrêa, T. X., Bomfim, C. V. D. A., Bueno, A. L. V., & Ribeiro, C. D. N. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408946
Pires, C. A. B., Leite, G. V., Gomes, I. B. D. A., & Bahia, J. P. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408941
Silva, F. M., Barros, A. C. L., Lana, J. G., & de Oliveira, B. M. M. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408954
Marcondes, L. C. R., de Oliveira, B. M. M., Batista, J. F. C., & Ferraz, V. C. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408951
de Miranda, D. R., Matos, B. S., Fernandes, G. M., & Brito, M. F. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408945
Ulhôa, S. F., Costa, C. S., Filho, F. M., & Lemos, G. S. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408939
CUIDADO PALIATIVO E ESPIRITUALIDADE
de Almeida, M. D. N. C. S., Andrade, I. A., Arêdes, L. R., & Cleveland, V. T. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408924
Garcia, G. M., Guimarães, C. M., Martins, D. C. S., & Júnior, M. D. S. G. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408927
Pires, C. A. B., Ferreira, A. L. L., Priori, D. P., & Salgado, M. G. R. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408942
Benatti, J. C. D. V., Batista, M. V. M., Chaves, L. S., & Flávio, L. M. S. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408943
PSIQUIATRIA PALIATIVA EM PACIENTES COM TRANSTORNOS MENTAIS SEVEROS
Barros, D. D. P., Lovaglio, L. V., de Oliveira, L. D., & Campos, P. S. S. D. O. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408947
Mansur, F. H., Lima, A. C. D. S., Teixeira, R. G. L., & Martins, T. G. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408950
Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks
Fonseca, P. E. O., Azevedo, J. A., Bié, S. M. G., & Ferreira, S. B. (2024) · Archives of Pharmacy and Pharmaceutical Sciences · doi:10.29328/journal.apps.1001055
Diabetische Nephropathie 2023 – Beginn eines neuen Zeitalters
Lindner, T. H., & Scherbaum, W. A. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01201-0
Inzucchi, S. E., Wanner, C., Fitchett, D., Zinman, B., Anker, S. D., Pocock, S., Mattheus, M., Hantel, S., & Lund, S. S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111715
Review of the top nephrology studies of 2020-2023
Wilson, J.-A. S., Pitman, J., Marin, J., Wazny, L. D., & Battistella, M. (2024) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635241250028
An update on the treatment of heart failure in people with diabetes: news from the ESC guidelines
Tuccinardi, F. (2024) · The Journal of AMD · doi:10.36171/jamd24.27.1.9
Revisiting a “Paradigm” in Cardiovascular and Kidney Disease
Chertow, G. M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.018
Wo, E., Trulli, C., Wilczynski, J. A., & Gonzalez, J. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241256772 · Cited by 1
Barroso, E. C., & Rosselló, X. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3321
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · medRxiv · doi:10.1101/2024.05.28.24308079
Effets cardio- et néphroprotecteurs des inhibiteurs du SGLT2
La, L., & Maione, L. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.05.026
Smetana, G. W., Romeo, G. R., Rosas, S. E., & Burns, R. B. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0764 · Cited by 2
Mima, A., NAKAMOTO, T., Matsumoto, K., Saito, Y., Morikawa, T., & Lee, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4439568/v1
Koshino, A. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1034863022
Locatelli, F., Paoletti, E., Ravera, M., Bella, G. P., & Vecchio, L. D. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374039 · Cited by 1
Dapagliflozin - new solution in chronic kidney disease treatment
Bara, M., Starownik, J., Szydło, J., Gryszkiewicz, P., & Nieznański, J. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.195
Managing Heart Failure in Chronic Kidney Disease: A Review of Current Literature
Lidgard, B., & Bansal, N. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01048-0 · Cited by 1
Podocyte injury in extreme obesity
Tsuboi, N., Okabayashi, Y., & Haruhara, K. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01578-4
Die Herausforderung der Lupusnephritis
Zimmermann, J. (2024) · Nephrologie aktuell · doi:10.1055/a-2275-4681
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. E. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2318-3452
Nephrology: a flourishing field with plentiful emerging topics
Yoo, K. D., & Chao, C. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1463540
Lanthier, L., Mutchmore, A., Plourde, M.-É., et al. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.07.011
Thompson, K., Bowers, B. L., & Evans, A. M. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102177
Wei, J., Zeng, X., Ji, K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4749865/v1
Davies, E. M., Anwar, N., Austin, P. J., Wong, C., Devonald, M. A. J., Lip, G. Y. H., Oni, L., McDowell, G., & Rao, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4844585/v1
Janota, O., Kwiendacz, H., Olejarz, A., Włosowicz, A., Pabis, P., Gumprecht, J., Alam, U., Lip, G. Y. H., & Nabrdalik, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2392017
GLP-1-receptoragonisten en renoprotectie in type 2-diabetes
Muskiet, M. H. A., & Apperloo, E. M. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1567-6
Liu, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1418575 · Cited by 2
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protectionPreprint
Jansz, T. T., Young, K., Hopkins, R., et al. (2024) · medRxiv · doi:10.1101/2024.09.01.24312905
IgA Nephropathy – Current and Future Perspectives in Treatment
Graňák, K., Vnučák, M., Beliančinová, M., Patricia, K., Blichová, T., Pytliaková, M., & Dedinská, I. (2024) · Acta Medica Martiniana · doi:10.2478/acm-2024-0011
5. Progress in Treatment of Kidney Diseases
Wada, T. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1535
Stopping Trials Early for Benefit
Kaul, S., & Butler, J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.026
See, A. Y. S., Blazeska, E., Shaban, A. A., Thomas, M. R., Nejad, S. H., Dornelles, A. S., Joyson, A., Burrows, S., Schlaich, M. P., & Thiruvengadam, S. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000541568 · Cited by 1
Huang, Y., Jiang, R., Ni, J., Li, J., & Wu, B. (2024) · Research Square · doi:10.21203/rs.3.rs-4982280/v1
Aktueller Stand der Nephroprotektion in der Diabetologie
Schmieder, R. E., & Striepe, K. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01235-4
Rapport 24-09. Changement de paradigme dans les maladies cardio-néphro-métaboliques
Reach, G., & Jaffiol, C. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.10.002 · Cited by 2
Warren, S., McKee, S., & Yakiwchuk, E. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.350
Pathophysiology of cardiorenal syndrome (CRS)
Menon, T., Martinez, V., Castro, M., & Vijayaraghavan, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00001-2
A Comprehensive Approach to Managing People With Diabetes and Chronic Kidney Disease
Cutrell, S., Zbyrak, V., Wheeler, S. E., Bucheit, J. D., & Khan, R. W. (2024) · ADCES in Practice · doi:10.1177/2633559x241280305
Fan, Y., & Wang, N. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003273 · Cited by 1
Cardiovascular and Renal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors
赵, 晨. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14102644
Pharmacotherapeutic Strategies to Prevent Progression to ESKD and Reduce Cardiovascular Risk
Odutayo, A., & Cherney, D. (2024) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00222024 · Cited by 1
Levin, A., & Stevens, P. E. (2024) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00382024
Matsumoto, S., Ito, H., Inoue, H., Chiaki, I., Miura, S., Antoku, S., Yamasaki, T., Mori, T., & Togane, M. (2024) · JMA Journal · doi:10.31662/jmaj.2024-0128 · Cited by 2
Sriswa, J., Chaiprasert, A., Supasyndh, O., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4962398/v1
Krüger, T. (2024) · Diabetes aktuell · doi:10.1055/a-2401-3920
YOSHIDA, Y., Yamada, H., & Sato, J. (2024) · In Vivo · doi:10.21873/invivo.13756
Hong, D., Hong, M., Kim, O., Shin, H.-Y., Bak, M., Kim, D., Kim, J., Choi, K. H., Kim, E. K., Lee, J. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5002803
I farmaci SGLT-2 inibitori: utilizzi nella pratica clinica oltre il diabete
Varaldo, E., Berton, A. M., Cuboni, D., & Grottoli, S. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01540-6
Murdock, D. K. (2024) · Insights in Biology and Medicine · doi:10.29328/journal.ibm.1001028
German, J., Yang, Z., Urbut, S., et al. (2024) · medRxiv · doi:10.1101/2024.11.05.24316763
Risk factors for progression in patients with KDOQI stage 3 Chronic Kidney Disease (PROGRESER study)
Martínez‐Castelao, A., Teruel, J. L., D’Marco, L., Garrigós, E., Fernández-Fresnedo, G., Espinel, E., Guldris, S. C., Coloma, J. A., Pérez-Monteoliva, N. R. R., de la Rosa, J. R. E., et al. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.10.002 · Cited by 5
Ishizaki, Y., Kikuchi, M., Kaikita, K., & Fujimoto, S. (2024) · Physiological Reports · doi:10.14814/phy2.70121
당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
Choi, J. H., & Moon, M. K. (2024) · Public Health Weekly Report · doi:10.56786/phwr.2024.17.44.4
Pinter, J., Tunnicliffe, D. J., Karunikaikumar, P., et al. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02672-4
Azzopardi, G., & Prowle, J. R. (2024) · Springer eBooks · doi:10.1007/978-3-031-66541-7_34
New Insights into Kidney Diseases
Katayama, K., & Dohi, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312536
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B., & Guthoff, M. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0591
Minimal-Change-Disease (MCD) und fokal-segmentale Glomerulosklerose
Osterholt, T., Benzing, T. R., & Brinkkötter, P. T. (2024) · Die Nephrologie · doi:10.1007/s11560-024-00814-2
Higashi, Y., Koga, K., Hasebe, M., Fukushima, C., Omiya, C., Nishioka, K., Nozu, K., & Yahata, K. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4485-24
Ito, S. (2024) · European Journal of Biomedical Research · doi:10.24018/ejbiomed.2024.3.5.106
“It was initially used as a treatment for diabetes mellitus (DM) [2] and eventually applied in the management of various heart failure conditions [3] and chronic kidney disease (CKD) [4].”
A gyógyszer-repozicionálás és klinikai diabetológiai vonatkozásai
Pokoly, B., & Somogyi, A. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33177
Evidenzbasierte Therapie von Hyperphosphatämie und Vitamin-D-Mangel
Heine, G. H. (2024) · Nephrologie aktuell · doi:10.1055/a-2415-9576
Aberle, J., Blüher, M., Laudes, M., Merkel, M., & Sandow, P. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2435-6818
“Todes-fälle jedweder Ursache konnten nicht signifikant gesenkt werden [54].”
Denny, O., Albanese, N. P., Meaney, C. J., Siwarski, N. E., & Monte, S. V. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241302731
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B., & Guthoff, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01273-y
Diabetic Nephropathy in Advanced Age Patients
Argyropoulos, C., & Roumelioti, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-68460-9_8
Do You Have Diabetes Mellitus?: How Diabetes and Its Treatments Are Linked to Kidney Disease
Rayner, H. C., Thomas, M. E., Dasgupta, I., Lalayiannis, A. D., & Hameed, M. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-66349-9_7
Cost-utility analysis of empagliflozin for heart failure in the Philippines
Montilla, P. J., Aquino, C. O., Cunanan, E. L., Encarnacion, P. J., Ong-Garcia, H. N., Llanes, E. J. B., Orolfo, D. D., Permejo, C. C., Taneo, M. J., Villanueva, A. R., et al. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2024.2447180 · Cited by 1
“This may have led to a conservative ICER result, considering evidence showing that empagliflozin slows CKD progression 40,41 .”
Behandlung der chronischen Nierenkrankheit bei IgA-Nephropathie
Schricker, S., Schanz, M., & Latus, J. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2255-6329
Marx-Schütt, K., Kintscher, U., Dahm, J. B., Fliser, D., Heine, G. H., Hoyer, J. D., Jung, C., Mahfoud, F., Ott, I., Schlieper, G., et al. (2025) · Die Kardiologie · doi:10.1007/s12181-024-00716-6
(2000) · Time to knit · doi:10.1016/s1166-4568(23)46240-7
da Fonseca, F. G., Piedade, A., Mendes, B., Inácio, A. D. S., Pereira, R., Côrte-Real, M., Soares, E., Carreira, J., & Soto, K. (2025) · Nefrología Latinoamericana · doi:10.24875/nefro.24000024
SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America
Daza, J. L., Gutiérrez, G., Murcia, R. L. P., Cárdenas, A., & Bello, J. S. R. (2025) · Nefrología Latinoamericana · doi:10.24875/nefro.24000019
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.